Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 96 of 110 Updated Nov 17, 2026

PE-22-28

Spadin analog

PRECLINICAL · SPADIN-DERIVED PEPTIDE; TREK-1 CHANNEL BLOCKER

▓ 3 indexed citations across PubMed (1), EuropePMC (2).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

3 citations across 1 tier

Tap any tier to jump to that section of the bibliography.

Mechanism of action

TREK-1 potassium channel inhibition; enhances serotonergic transmission; neurogenesis

Researched effects

TREK-1 inhibition; antidepressant effect; neurogenesis

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

200-500 mcg SC daily (research)

Known concerns

Very limited human data

Top-ranked picks

3 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Role of TREK-1 in Health and Disease, Focus on the Central Nervous System.

    2019 — RESEARCH ARTICLES · AUTHORITY 33.9

  2. Retroinverso analogs of spadin display increased antidepressant effects.

    2015 — RESEARCH ARTICLES · AUTHORITY 33.5

  3. Shortened Spadin Analogs Display Better TREK-1 Inhibition,

    Frontiers in pharmacology · 2017 — RESEARCH ARTICLES · AUTHORITY 31.7

Full citation library

Year distribution

Research Articles

3
  1. 1.

    Djillani A, Pietri M, Moreno S, Heurteaux C, et al. · Frontiers in pharmacology · 2017 · PMID 28955242

    Depression is a devastating mental disorder that affects 20% of the population worldwide. Despite their proven efficacy, antidepressants present a delayed onset of action and serious adverse effects. Seven years ago, we described spadin (PE 12-28) as a promising endogenous peptide with antidepressant activity. Spadin specifically blocks the TREK-1 channel. Previously, we showed

  2. 2.

    Veyssiere J, Moha Ou Maati H, Mazella J, Gaudriault G, Moreno S, Heurteaux C, Borsotto M. · 2015 · PMID 25080852

    <h4>Rationale</h4>Although depression is the most common mood disorder, only one third of patients are treated with success. Finding new targets, new drugs, and also new drug intake way are the main challenges in the depression field. Several years ago, we identified a new target with the TWIK-related potassium channel-1 (TREK-1) potassium channel, and more recently, we have discovered a peptide of 17 amino acids with antidepressant properties. This peptide, that we called spadin, can be conside…

  3. 3.

    Djillani A, Mazella J, Heurteaux C, Borsotto M. · 2019 · PMID 31031627

    TREK-1 is the most studied background K<sub>2P</sub> channel. Its main role is to control cell excitability and maintain the membrane potential below the threshold of depolarization. TREK-1 is multi-regulated by a variety of physical and chemical stimuli which makes it a very promising and challenging target in the treatment of several pathologies. It is mainly expressed in the brain but also in heart, smooth muscle cells, endocrine pancreas, and prostate. In the nervous system, TREK-1 is involv…

Curated sources on file

2
  1. 1.
  2. 2.
    Note: Preclinical evidence only — no published human clinical trials. Cited paper describes in-vitro or animal-model mechanism.

Continue reading